212 related articles for article (PubMed ID: 17609921)
1. [PDE5 inhibitors in treatment of benign prostatic syndrome].
Sandner P; Tinel H; Stelte-Ludwig B; Huetter J; Neuser D; Bischoff E; Ulbrich E
Urologe A; 2007 Sep; 46(9):1189-92. PubMed ID: 17609921
[No Abstract] [Full Text] [Related]
2. [PDE5 inhibitors. A new option in the treatment of ureteral colic?].
Gratzke C; Uckert S; Reich O; Schlenker B; Tilki D; Seitz M; Stief CG
Urologe A; 2007 Sep; 46(9):1219-23. PubMed ID: 17604974
[TBL] [Abstract][Full Text] [Related]
3. Failure of PDE5 inhibitor use: a case of nonresponder? (CME).
Chung E
J Sex Med; 2010 Apr; 7(4 Pt 1):1321-3. PubMed ID: 20492423
[No Abstract] [Full Text] [Related]
4. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
5. Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report.
Agrawal A; Tutuian R; Hila A; Castell DO
Dig Dis Sci; 2005 Nov; 50(11):2059-62. PubMed ID: 16240215
[No Abstract] [Full Text] [Related]
6. [Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].
Herlemann A; Gratzke C; Andersson KE; Sievert KD
Urologe A; 2013 Feb; 52(2):204-11. PubMed ID: 23417046
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
8. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
9. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
10. Erectile dysfunction.
Katz A; Katz A
CMAJ; 2010 Mar; 182(4):381-2. PubMed ID: 20142374
[No Abstract] [Full Text] [Related]
11. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
[TBL] [Abstract][Full Text] [Related]
12. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.
Jannini EA; Isidori AM; Gravina GL; Aversa A; Balercia G; Bocchio M; Boscaro M; Carani C; Corona G; Fabbri A; Foresta C; Forti G; Francavilla S; Granata AR; Maggi M; Mansani R; Palego P; Spera G; Vetri M; Lenzi A;
J Sex Med; 2009 Sep; 6(9):2547-60. PubMed ID: 19570039
[TBL] [Abstract][Full Text] [Related]
13. Patient education series. Erectile dysfunction.
Lewis JH; Rosen R; Goldstein I
Nursing; 2005 Feb; 35(2):64. PubMed ID: 15706284
[No Abstract] [Full Text] [Related]
14. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.
Vignozzi L; Gacci M; Cellai I; Morelli A; Maneschi E; Comeglio P; Santi R; Filippi S; Sebastianelli A; Nesi G; Serni S; Carini M; Maggi M
Prostate; 2013 Sep; 73(13):1391-402. PubMed ID: 23765639
[TBL] [Abstract][Full Text] [Related]
15. How new drugs help treat erectile dysfunction.
Weeks B; Ficorelli CT
Nursing; 2006 Jan; 36(1):18-9. PubMed ID: 16394991
[No Abstract] [Full Text] [Related]
16. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
Doggrell S
Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
[TBL] [Abstract][Full Text] [Related]
17. [Phosphodiesterase inhibitors: effectiveness and new applications].
van Driel MF
Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1613-6. PubMed ID: 16901064
[TBL] [Abstract][Full Text] [Related]
18. Erectile dysfunction and the drugs to treat it. In many cases, medications are all a man needs to stay sexually active.
Harv Health Lett; 2014 May; 39(7):7. PubMed ID: 25073193
[No Abstract] [Full Text] [Related]
19. Phosphodiesterase 5 inhibition in essential hypertension.
Ghiadoni L; Versari D; Taddei S
Curr Hypertens Rep; 2008 Feb; 10(1):52-7. PubMed ID: 18367027
[TBL] [Abstract][Full Text] [Related]
20. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract.
Fibbi B; Morelli A; Vignozzi L; Filippi S; Chavalmane A; De Vita G; Marini M; Gacci M; Vannelli GB; Sandner P; Maggi M
J Sex Med; 2010 Jan; 7(1 Pt 1):59-69. PubMed ID: 19796053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
